Literature DB >> 19389436

siRNA vs. shRNA: similarities and differences.

Donald D Rao1, John S Vorhies, Neil Senzer, John Nemunaitis.   

Abstract

RNA interference (RNAi) is a natural process through which expression of a targeted gene can be knocked down with high specificity and selectivity. Using available technology and bioinformatics investigators will soon be able to identify relevant bio molecular tumor network hubs as potential key targets for knockdown approaches. Methods of mediating the RNAi effect involve small interfering RNA (siRNA), short hairpin RNA (shRNA) and bi-functional shRNA. The simplicity of siRNA manufacturing and transient nature of the effect per dose are optimally suited for certain medical disorders (i.e. viral injections). However, using the endogenous processing machinery, optimized shRNA constructs allow for high potency and sustainable effects using low copy numbers resulting in less off-target effects, particularly if embedded in a miRNA scaffold. Bi-functional design may further enhance potency and safety of RNAi-based therapeutics. Remaining challenges include tumor selective delivery vehicles and more complete evaluation of the scope and scale of off-target effects. This review will compare siRNA, shRNA and bi-functional shRNA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19389436     DOI: 10.1016/j.addr.2009.04.004

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  168 in total

1.  Intrathecal injection of TRPV1 shRNA leads to increases in blood pressure in rats.

Authors:  S-Q Yu; D H Wang
Journal:  Acta Physiol (Oxf)       Date:  2011-04-22       Impact factor: 6.311

2.  Development of a siRNA and shRNA screening system based on a kinase fusion protein.

Authors:  Sofie Pieraets; Luk Cox; Olga Gielen; Jan Cools
Journal:  RNA       Date:  2012-04-26       Impact factor: 4.942

Review 3.  Delivery of siRNA therapeutics: barriers and carriers.

Authors:  Jie Wang; Ze Lu; M Guillaume Wientjes; Jessie L-S Au
Journal:  AAPS J       Date:  2010-06-11       Impact factor: 4.009

Review 4.  Designing highly active siRNAs for therapeutic applications.

Authors:  S Patrick Walton; Ming Wu; Joseph A Gredell; Christina Chan
Journal:  FEBS J       Date:  2010-12       Impact factor: 5.542

Review 5.  Polymer nanoparticles for drug and small silencing RNA delivery to treat cancers of different phenotypes.

Authors:  Rammohan Devulapally; Ramasamy Paulmurugan
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2013-08-31

Review 6.  RNA interference and cancer therapy.

Authors:  Zhaohui Wang; Donald D Rao; Neil Senzer; John Nemunaitis
Journal:  Pharm Res       Date:  2011-10-19       Impact factor: 4.200

7.  Effects of C-myc gene silencing on interleukin-1β-induced rat chondrocyte cell proliferation, apoptosis and cytokine expression.

Authors:  Jian Zou; Xiao-Lin Li; Zhong-Min Shi; Jian-Feng Xue
Journal:  J Bone Miner Metab       Date:  2017-06-14       Impact factor: 2.626

Review 8.  In vivo delivery of miRNAs for cancer therapy: challenges and strategies.

Authors:  Yunching Chen; Dong-Yu Gao; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2014-05-22       Impact factor: 15.470

9.  Evaluation of a Novel Plasmid for Simultaneous Gene Electrotransfer-Mediated Silencing of CD105 and CD146 in Combination with Irradiation.

Authors:  Monika Savarin; Urska Kamensek; Katarina Znidar; Vesna Todorovic; Gregor Sersa; Maja Cemazar
Journal:  Int J Mol Sci       Date:  2021-03-17       Impact factor: 5.923

10.  Comparative analysis of RNAi screening technologies at genome-scale reveals an inherent processing inefficiency of the plasmid-based shRNA hairpin.

Authors:  Bhavneet Bhinder; David Shum; Hakim Djaballah
Journal:  Comb Chem High Throughput Screen       Date:  2014-02       Impact factor: 1.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.